Clinical trials: Non-infectious Anterior Uveitis, open to volunteers
Non-infectious Anterior Uveitis, Non-infectious Intermediate Uveitis
Efficacy and Safety of Adalimumab for the Treatment of Ocular Inflammation
This study aims to evaluate the clinical efficacy and safety of adalimumab in pediatric non-infectious uveitis and to generate domestic real-world evidence (RWE), thereby establishing a clinical foundation for label expansion and…
- Conditions
- Non-infectious Anterior Uveitis, Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Panuveitis
- Trial name
- PANDA-U (NCT07913750)
- Testing
- Adalimumab PFS and Pen
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Samsung Medical Center
Active Non-anterior, Non-infectious Uveitis
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIU
The purpose of this study is to find out the efficacy and safety of oral FXS5626 in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).
- Trial name
- NCT07552012
- Testing
- FXS5626 tablet
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Non-infectious Anterior Uveitis
Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis
The primary objective of the study is to investigate the safety and tolerability of NOV05 eye drops at two concentrations QID in patients with active non-infectious anterior uveitis.
- Trial name
- EYETAC (NCT07285070)
- Testing
- Tacrolimus ophthalmic solution
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- Novaliq GmbH
Active Non-anterior Non-infectious Uveitis
Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis
The aim of the study is to evaluate the efficacy of Baricitinib, a JAK1 and 2 inhibitor, in the management of non-infectious non-anterior uveitis refractory to at least one line of biotherapy (anti-TNF alpha, tocilizumab) after 6…
- Trial name
- JAKUVEITE (NCT05651880)
- Testing
- Baricitinib 4 MG
- Where
- France
- Volunteers
- 33 people
- Sponsor
- University Hospital, Rouen